Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jonathan M Edelman

Showing results (41-50 of 44) with videos related to

Pageof 5
Sort By:
You have reached the last page of results.This site can display upto 44 results.
Journal of Hypertension|August 27, 2002
Risk of new-onset diabetes in the Losartan Intervention For Endpoint reduction in hypertension studyLars H Lindholm, Hans Ibsen, Knut Borch-Johnsen, et al.
Hypertension (Dallas, Tex. : 1979)|December 8, 2004
Stroke reduction in hypertensive adults with cardiac hypertrophy randomized to losartan versus atenolol: the Losartan Intervention For Endpoint reduction in hypertension studyJorge R Kizer, Björn Dahlöf, Sverre E Kjeldsen, et al.
The Lancet. Respiratory Medicine|December 6, 2016
Long-term efficacy and safety of α1 proteinase inhibitor treatment for emphysema caused by severe α1 antitrypsin deficiency: an open-label extension trial (RAPID-OLE)Noel G McElvaney, Jonathan Burdon, Mark Holmes, et al.
Nature Communications|May 14, 2024
Safety, immunogenicity and efficacy of the self-amplifying mRNA ARCT-154 COVID-19 vaccine: pooled phase 1, 2, 3a and 3b randomized, controlled trialsNhân Thị Hồ, Steven G Hughes, Van Thanh Ta, et al.
Pageof 5

Showing results (41-50 of 44) with videos related to

Sort By:
Pageof 5
You have reached the last page of results.This site can display upto 44 results.
Journal of Hypertension|August 27, 2002
Risk of new-onset diabetes in the Losartan Intervention For Endpoint reduction in hypertension studyLars H Lindholm, Hans Ibsen, Knut Borch-Johnsen, et al.
Hypertension (Dallas, Tex. : 1979)|December 8, 2004
Stroke reduction in hypertensive adults with cardiac hypertrophy randomized to losartan versus atenolol: the Losartan Intervention For Endpoint reduction in hypertension studyJorge R Kizer, Björn Dahlöf, Sverre E Kjeldsen, et al.
The Lancet. Respiratory Medicine|December 6, 2016
Long-term efficacy and safety of α1 proteinase inhibitor treatment for emphysema caused by severe α1 antitrypsin deficiency: an open-label extension trial (RAPID-OLE)Noel G McElvaney, Jonathan Burdon, Mark Holmes, et al.
Nature Communications|May 14, 2024
Safety, immunogenicity and efficacy of the self-amplifying mRNA ARCT-154 COVID-19 vaccine: pooled phase 1, 2, 3a and 3b randomized, controlled trialsNhân Thị Hồ, Steven G Hughes, Van Thanh Ta, et al.
Pageof 5